Welcome to Chinese Journal of Clinical Pharmacology and Therapeutics,Today is Chinese

Chinese Journal of Clinical Pharmacology and Therapeutics ›› 2025, Vol. 30 ›› Issue (1): 100-109.doi: 10.12092/j.issn.1009-2501.2025.01.012

Previous Articles     Next Articles

Drug resistance of tyrosine kinase inhibitors in renal cell carcinoma

QIAN Hanxu, ZHAO Yaxuan, YANG Yang, ZHANG Yin   

  1. School of Pharmacy, Binzhou Medical University, Yantai 264003, Shandong, China
  • Received:2024-01-24 Revised:2024-04-07 Online:2025-01-26 Published:2025-01-02

Abstract:

Tyrosine kinase inhibitors (TKIs) are the key agent in the treatment of renal cell carcinoma (RCC) so far. Drugs such as sunitinib and sorafenib showed significant benefits RCC patients, however, the adverse effect, drug efficacy and drug resistance limited the use of these therapy. Especially the drug resistant issue brings up a big challenge for clinical practice, and the mechanisms underlying are still poorly understood. In recent years, new therapies have been combined with TKIs to improve the treatment outcome. Immunotherapy, combination therapy with other TKIs, targeted nanoparticle delivery, and drug modification are widely studied to improve the efficacies of TKIs and regain the sensitivity. In this review, we summarizes the current understanding of TKI drug resistance and the approaches to regaining drug sensitivity.

Key words: renal carcinoma, drug resistance, TKI, tumor angiogenesis, target therapy

CLC Number: